Spectrum Pharmaceuticals Inc. (SPPI)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052

Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.

Data as of 2020-07-04
Market Cap399.487 Million Shares Outstanding116.468 Million Avg 30-day Volume1.447 Million
P/E Ratio Dividend Yield EPS-1.2
Price/Sales Price cash flow ratio90.3 Price free cash flow ratio-4.3
Book Value1.32 Price to Tangible Book2.79 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.187228
BETA2.10087 52-week High/Low10.57 / 1.7422 Stddev0.20676
View SEC Filings from SPPI instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 1 (0.07%)
13F Filers holding this stock: 151 33 (2.16%)
Aggregate 13F shares on 03/31/2020: 69.679 Million 24.866 Million
Aggregate 13F shares on 12/31/2019: 77.399 Million 27.155 Million
Percent change: -9.97% -8.43%
Funds creating new positions: 23 9
Funds Adding to an existing position: 46 11
Funds closing out their position: 36 16
Funds reducing their position: 47 10
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SPPI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SPPI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

52.2 Thousand total shares from 9 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCGAHAN KEITH M CHIEF LEGAL OFFICER

  • Officer
255,563 2020-07-09 10

VACIRCA JEFF L

  • Director
74,967 2020-06-30 3

GUSTAFSON KURT A

  • Director
0 2020-06-25 4

ASHTON WILLIAM

  • Director
41,666 2020-06-22 2

LEBEL FRANCOIS CHIEF MEDICAL OFFICER

  • Officer
299,955 2020-06-22 4

VYAS DOLATRAI

  • Director
81,069 2020-06-18 1

WELLES BERNICE R

  • Director
50,000 2020-06-18 1

CZEREPAK ELIZABETH

  • Director
40,000 2020-06-18 1

FISCHER SETH H. Z.

  • Director
32,500 2020-06-18 3

SHROTRIYA RAJESH C MD

  • Director
0 2020-06-16 0

GUETH ANTON

  • Director
429,456 2020-06-11 0

RIGA THOMAS J EVP, COO & CCO

  • Officer
430,572 2020-05-13 5

MAIDA ANTHONY E III

198,668 2020-05-11 0

TURGEON JOSEPH W. CEO & PRESIDENT

  • Officer
  • Director
692,672 2020-03-31 4

COHEN RAYMOND W CHIEF EXECUTIVE OFFICER

542,058 2020-03-16 0

ALLEN LEE F MD PHD CHIEF MEDICAL OFFICER

  • Officer
0 2019-11-12 0

TIDMARSH GEORGE F

  • Director
151,291 2019-09-19 0

SCOTT BRETT L

  • Director
30,575 2019-07-23 0

KRASSNER STUART MITCHELL

  • Director
75,488 2019-05-24 0

GAGNON GILLES

  • Director
72,500 2018-10-09 0

LENAZ LUIGI MD

  • Director
109,077 2018-05-22 0

KELLER JOSEPH KENNETH EVP & CHIEF OPERATING OFFICER

  • Officer
168,000 2013-12-03 0

ARORA KRISHAN K

  • Director
15,000 2012-12-19 0

SHIELDS JAMES CHIEF COMMERCIAL OFFICER

  • Officer
0 2012-09-07 0

MEHTA DILIP J MD PHD

  • Director
0 2011-06-12 0

KUMARIA SHYAM K SR. VICE PRESIDENT FINANCE

  • Officer
No longer subject to file 2011-01-03 0

VIDA JULIUS A

  • Director
0 2010-04-20 0

FULMER RICHARD

  • Director
0 2010-04-20 0

CYBULSKI MITCHELL P.

  • Director
0 2010-04-20 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MCGAHAN KEITH M - Officer CHIEF LEGAL OFFICER

2020-07-09 S 13,881 $3.36 d 249,313 255,563.00 direct yes

VACIRCA JEFF L - Director

2020-06-30 A 8,000 $3.21 a 74,967 74,967.00 direct

MCGAHAN KEITH M - Officer CHIEF LEGAL OFFICER

2020-06-24 S 15,773 $3.21 d 262,986 269,236.00 direct yes

LEBEL FRANCOIS - Officer CHIEF MEDICAL OFFICER

2020-06-23 S 4,167 $3.35 d 292,729 299,955.00 direct yes

MCGAHAN KEITH M - Officer CHIEF LEGAL OFFICER

2020-06-22 S 3,000 $3.25 d 278,759 285,009.00 direct yes

LEBEL FRANCOIS - Officer CHIEF MEDICAL OFFICER

2020-06-22 S 5,474 $3.16 d 296,896 299,955.00 direct yes

ASHTON WILLIAM - Director

2020-06-22 S 5,000 $3.25 d 41,666 41,666.00 direct yes

MCGAHAN KEITH M - Officer CHIEF LEGAL OFFICER

2020-06-19 S 3,459 $3.13 d 281,759 285,009.00 direct yes

FISCHER SETH H. Z. - Director

2020-06-18 A 60,000 a 60,000 32,500.00 direct

WELLES BERNICE R - Director

2020-06-18 A 30,000 a 50,000 50,000.00 direct

VACIRCA JEFF L - Director

2020-06-18 A 60,000 a 60,000 66,967.00 direct

CZEREPAK ELIZABETH - Director

2020-06-18 A 30,000 a 40,000 40,000.00 direct

ASHTON WILLIAM - Director

2020-06-18 A 60,000 a 60,000 41,666.00 direct

FISCHER SETH H. Z. - Director

2020-06-18 A 30,000 a 32,500 32,500.00 direct

VYAS DOLATRAI - Director

2020-06-18 A 60,000 a 60,000 81,069.00 direct

VACIRCA JEFF L - Director

2020-06-18 A 30,000 a 66,967 66,967.00 direct

ASHTON WILLIAM - Director

2020-06-18 A 60,000 a 60,000 46,666.00 direct

WELLES BERNICE R - Director

2020-06-18 A 60,000 a 60,000 50,000.00 direct

VYAS DOLATRAI - Director

2020-06-18 A 30,000 a 81,069 81,069.00 direct

CZEREPAK ELIZABETH - Director

2020-06-18 A 60,000 a 60,000 40,000.00 direct

ASHTON WILLIAM - Director

2020-06-18 A 30,000 a 46,666 46,666.00 direct

VACIRCA JEFF L - Director

2020-05-15 A 5,000 $3.11 a 36,967 36,967.00 direct

MCGAHAN KEITH M - Officer CHIEF LEGAL OFFICER

2020-05-14 S 350 $3.06 d 285,218 291,468.00 direct yes

RIGA THOMAS J - Officer EVP, COO & CCO

2020-05-14 S 1,125 $3.06 d 416,433 430,572.00 direct yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments